|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Then, LCW was treated with BPH-1, a human BPH cell line, at 25, 50, 100 μg/mL for 24 h and examine mRNA level of androgen receptor (AR) and prostate-specific antigen (PSA).
|
30724641 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, 5<i>α</i>-reductase (5AR) and androgen receptor (AR), the two main factors in the pathogenesis of BPH, were decreased.
|
31467577 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall AR and ARV7 mRNA expression levels were increased in CRPC tissues compared to localized PCa and BPH tissues.
|
29756415 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that PRE altered testosterone-induced BPH in rats and retarded prostate cancer cell growth by modulating AR expression.
|
31489669 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was also found that diosmin downregulated the expression of androgen receptor and decreased the prostate-specific antigen concentration dose-dependently, significantly against TP-induced BPH.
|
31797688 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the protein expressions of AR, 5AR2, and PSA were significantly lower in the PE gavaged group than BPH group in prostate tissue.
|
31591335 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, BBR suppressed TP-associated increase of 5AR, androgen receptor (AR) and steroid coactivator-1 (SRC-1), the key factors in the pathogenesis of BPH.
|
30061836 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support the assumption that these constitutively active isoforms of AR are involved in the pathophysiology of primary PCa and BPH.
|
30028845 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The activation of androgen receptor (AR) signaling plays an essential role in both prostate stromal cells and epithelial cells during the development of benign prostatic hyperplasia (BPH).
|
29568063 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no significant difference in the mRNA and protein levels of iNOS, VEGF, AR and IL-2, IL-8 and TNF-α between PCa and BPH+HP groups (p > .05). iNOS, VEGF, AR and IL-2, IL-8 and TNF-α are involved in the malignant transformation of prostate tissue and play an important role in the development and progression of Prostate cancer (PCa).
|
29441606 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DSEE inhibited weight gain of the prostate; decreased mRNA expressions of androgen receptor and 5α-reductase II; and improved histopathological symptoms, the protein-expressed ratio of Bax/Bcl-2, and the oxidative status of BPH induced by testosterone in SD rats.
|
30124113 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarkers were evaluated including prostate weight, prostate weight ratio, hormonal changes, 5-α reductase type II androgen receptor (AR) of the prostate gland and anti-oxidant activation factors related to BPH.
|
28830494 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, the reverse transcription-polymerase chain reaction revealed downregulated mRNA expression levels of the androgen receptor, 5α-reductase, and B-cell lymphoma-2 (Bcl-2) in the BPH/CWW200 group compared with those in the testosterone-induced groups.
|
28953224 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesize that AR and different downstream inflammatory mediators between TZ and PZ could serve as potential targets for the future design of therapeutic agents for BPH and our results provide significant insights into the search for targeted therapeutic approaches to battle BPH.
|
28694768 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The elevated expressions of androgen receptor (AR), estrogen receptor α and steroid receptor coactivator 1 by TP administration were also inhibited in the CA group when compared to the TP-induced BPH group.
|
27880726 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This 5-HT's inhibitory mechanism is also present in human cells of normal prostate and BPH, namely in cell lines expressing AR when treated with testosterone.
|
29133842 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results show a fundamental role for NFIB as a coregulator of AR action in the prostate and in controlling prostatic hyperplasia.
|
26677878 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The objective of the study was to evaluate and compare the androgen receptor (AR) expression in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and prostatic adenocarcinoma.
|
27072221 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that decreased expression of the androgen receptor (AR) in luminal cells of human BPH specimens correlates with a higher degree of regional prostatic inflammation.
|
27594448 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NF-κB activation and androgen receptor variant (AR-V) expression were quantified in transition zone tissue samples from patients with a wide range of AUASS from incidental BPH in patients treated for low grade, localized peripheral zone prostate cancer to advanced disease requiring surgical intervention.
|
26709083 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that NF-κB and AR-V7 upregulate SRD5A expression providing a mechanism to explain failure of 5ARI therapy in BPH patients.Prostate 76:1004-1018, 2016.
|
27197599 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relationships between male androgenetic alopecia, androgen receptor (AR) gene polymorphism (SNP rs6152) and clinical characteristics of BPH and prostate cancer.
|
24665929 |
2015 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of Aurora B and AR were investigated in 23 benign prostatic hyperplasia and 38 prostate cancer specimens.
|
25277659 |
2015 |
|
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found no statistically significant differences in allelic % of the AR-E211 G > A polymorphism between BPH and CaP patients (p ≤ 0.8462).
|
24634161 |
2014 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In PCa tissues, the levels of both immunoreactive ZEB2 and androgen receptor (AR) were found to be significantly higher (P<0.05) when compared with BPH tissues.
|
24812058 |
2014 |